Tumor growth of neurofibromin-deficient cells is driven by decreased respiration and hampered by NAD+ and SIRT3

Cell Death Differ. 2022 Oct;29(10):1996-2008. doi: 10.1038/s41418-022-00991-4. Epub 2022 Apr 7.

Abstract

Neurofibromin loss drives neoplastic growth and a rewiring of mitochondrial metabolism. Here we report that neurofibromin ablation dampens expression and activity of NADH dehydrogenase, the respiratory chain complex I, in an ERK-dependent fashion, decreasing both respiration and intracellular NAD+. Expression of the alternative NADH dehydrogenase NDI1 raises NAD+/NADH ratio, enhances the activity of the NAD+-dependent deacetylase SIRT3 and interferes with tumorigenicity in neurofibromin-deficient cells. The antineoplastic effect of NDI1 is mimicked by administration of NAD+ precursors or by rising expression of the NAD+ deacetylase SIRT3 and is synergistic with ablation of the mitochondrial chaperone TRAP1, which augments succinate dehydrogenase activity further contributing to block pro-neoplastic metabolic changes. These findings shed light on bioenergetic adaptations of tumors lacking neurofibromin, linking complex I inhibition to mitochondrial NAD+/NADH unbalance and SIRT3 inhibition, as well as to down-regulation of succinate dehydrogenase. This metabolic rewiring could unveil attractive therapeutic targets for neoplasms related to neurofibromin loss.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • HSP90 Heat-Shock Proteins / metabolism
  • Humans
  • NAD / metabolism
  • NADH Dehydrogenase / metabolism
  • Neoplasms*
  • Neurofibromin 1 / genetics
  • Neurofibromin 1 / metabolism
  • Respiration
  • Sirtuin 3* / genetics
  • Sirtuin 3* / metabolism
  • Succinate Dehydrogenase / metabolism

Substances

  • HSP90 Heat-Shock Proteins
  • Neurofibromin 1
  • TRAP1 protein, human
  • NAD
  • Succinate Dehydrogenase
  • NADH Dehydrogenase
  • SIRT3 protein, human
  • Sirtuin 3